Genmab CEO: "We can do things in a smarter way than pharma companies"

After releasing a positive report for the second quarter, CEO Jan van de Winkel tells MedWatch how Genmab can beat traditional pharmaceutical companies on sales in the future.

Genmab CEO Jan van de Winkel

Although sales of the first drug Genmab is helping to commercialize itself, Tivdak, pale in comparison to its bestseller Darzalex, which is sold by partner Janssen, CEO Jan van de Winkel says that the experience of marketing its own product has gone better than anticipated.

According to the Q2 report, cervical cancer treatment Tivdak generated DKK 91m (USD 12.6m) in sales during the period.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs